Patents by Inventor Bruce A. Andrien

Bruce A. Andrien has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-C5 ANTIBODIES HAVING IMPROVED PHARMACOKINETICS
    Publication number: 20250145698
    Abstract: The disclosure provides antibodies that are useful for, among other things, inhibiting terminal complement (e.g., the assembly and/or activity of the C5b-9 TCC) and C5a anaphylatoxin-mediated inflammation and, thus, treating complement-associated disorders. The antibodies have a number of improved properties relative to eculizumab, including, e.g., increased serum half-life in a human.
    Type: Application
    Filed: January 9, 2025
    Publication date: May 8, 2025
    Inventors: Bruce A. Andrien, JR., Douglas L. SHERIDAN, Paul P. TAMBURINI, Yi WANG
  • KIDNEY ACTIVE FUSION PROTEINS AND METHODS OF TREATMENT USING THE SAME
    Publication number: 20240262877
    Abstract: Described herein are fusion proteins which include factor H catalytic domains and may include VHH domains, factor H-related protein 5 domains, or integrin binding domains, and the use of such fusion proteins in methods of treatment of diseases mediated by complement alternative pathway activation or dysregulation, for example, kidney diseases.
    Type: Application
    Filed: May 24, 2022
    Publication date: August 8, 2024
    Applicant: Alexion Pharmaceuticals, Inc.
    Inventors: Keith Bouchard, Jeffrey William Hunter, Bruce A. Andrien, Jr., Sung-Kwon Kim, Julian Chandler
  • ANTI-C5 ANTIBODIES HAVING IMPROVED PHARMACOKINETICS
    Publication number: 20240141024
    Abstract: The disclosure provides antibodies that are useful for, among other things, inhibiting terminal complement (e.g., the assembly and/or activity of the C5b-9 TCC) and C5a anaphylatoxin-mediated inflammation and, thus, treating complement-associated disorders. The antibodies have a number of improved properties relative to eculizumab, including, e.g., increased serum half-life in a human.
    Type: Application
    Filed: July 7, 2023
    Publication date: May 2, 2024
    Inventors: Bruce A. ANDRIEN, JR., Douglas L. SHERIDAN, Paul P. TAMBURINI, Yi WANG
  • Method of quantitating unbound C5 in a sample
    Patent number: 11965884
    Abstract: A method of quantitating free (unbound) human C5 complement protein (C5) from a sample comprising: binding biotinylated anti-C5 capture antibody to strepavidin-coated particles; capturing the free (unbound) C5 in the sample; detecting the captured free C5; and quantitating the captured free C5 using laser-induced fluorescence detection; wherein the method is performed in a Gyros Bioaffy 200 CD in a Gyrolab xPlore or a Gyrolab XP instrument.
    Type: Grant
    Filed: October 19, 2017
    Date of Patent: April 23, 2024
    Assignee: Alexion Pharmaceuticals, Inc.
    Inventors: Mark Dysinger, Mark Ma, Bruce A. Andrien
  • Anti-C5 antibodies having improved pharmacokinetics
    Patent number: 11434280
    Abstract: The disclosure provides antibodies that are useful for, among other things, inhibiting terminal complement (e.g., the assembly and/or activity of the C5b-9 TCC) and C5a anaphylatoxin-mediated inflammation and, thus, treating complement-associated disorders. The antibodies have a number of improved properties relative to eculizumab, including, e.g., increased serum half-life in a human.
    Type: Grant
    Filed: January 23, 2020
    Date of Patent: September 6, 2022
    Assignee: Alexion Pharmaceuticals, Inc.
    Inventors: Bruce A. Andrien, Jr., Douglas L. Sheridan, Paul P. Tamburini, Yi Wang
  • ANTI-C5 ANTIBODIES HAVING IMPROVED PHARMACOKINETICS
    Publication number: 20200157200
    Abstract: The disclosure provides antibodies that are useful for, among other things, inhibiting terminal complement (e.g., the assembly and/or activity of the C5b-9 TCC) and C5a anaphylatoxin-mediated inflammation and, thus, treating complement-associated disorders. The antibodies have a number of improved properties relative to eculizumab, including, e.g., increased serum half-life in a human.
    Type: Application
    Filed: January 23, 2020
    Publication date: May 21, 2020
    Inventors: Bruce A. ANDRIEN, Jr., Douglas L. SHERIDAN, Paul P. TAMBURINI, Yi WANG
  • Methods of treating atypical hemolytic uremic syndrome and paroxysmal nocturnal hemoglobinuria with anti-C5 antibodies
    Patent number: 10584164
    Abstract: The disclosure provides antibodies that are useful for, among other things, inhibiting terminal complement (e.g., the assembly and/or activity of the C5b-9 TCC) and C5a anaphylatoxin-mediated inflammation and, thus, treating complement-associated disorders. The antibodies have a number of improved properties relative to eculizumab, including, e.g., increased serum half-life in a human.
    Type: Grant
    Filed: January 14, 2019
    Date of Patent: March 10, 2020
    Assignee: Alexion Pharmaceuticals, Inc.
    Inventors: Bruce A. Andrien, Jr., Douglas L. Sheridan, Paul P. Tamburini, Yi Wang
  • ANTI-C5 ANTIBODIES HAVING IMPROVED PHARMACOKINETICS
    Publication number: 20190263897
    Abstract: The disclosure provides antibodies that are useful for, among other things, inhibiting terminal complement (e.g., the assembly and/or activity of the C5b-9 TCC) and C5a anaphylatoxin-mediated inflammation and, thus, treating complement-associated disorders. The antibodies have a number of improved properties relative to eculizumab, including, e.g., increased serum half-life in a human.
    Type: Application
    Filed: January 14, 2019
    Publication date: August 29, 2019
    Inventors: Bruce A. Andrien, JR., Douglas L. Sheridan, Paul P. Tamburini, Yi Wang
  • A METHOD OF QUANTITATING UNBOUND C5 IN A SAMPLE
    Publication number: 20190250157
    Abstract: A method of quantitating free (unbound) human C5 complement protein (C5) from a sample comprising: binding biotinylated anti-C5 capture antibody to strepavidin-coated particles; capturing the free (unbound) C5 in the sample; detecting the captured free C5; and quantitating the captured free C5 using laser-induced fluorescence detection; wherein the method is performed in a Gyros Bioaffy 200 CD in a Gyrolab xPlore or a Gyrolab XP instrument.
    Type: Application
    Filed: October 19, 2017
    Publication date: August 15, 2019
    Inventors: Mark DYSINGER, Mark MA, Bruce A. ANDRIEN
  • Methods of treating atypical hemolytic uremic syndrome with anti-C5 antibodies
    Patent number: 10227400
    Abstract: The disclosure provides antibodies that are useful for, among other things, inhibiting terminal complement (e.g., the assembly and/or activity of the C5b-9 TCC) and C5a anaphylatoxin-mediated inflammation and, thus, treating complement-associated disorders. The antibodies have a number of improved properties relative to eculizumab, including, e.g., increased serum half-life in a human.
    Type: Grant
    Filed: September 19, 2017
    Date of Patent: March 12, 2019
    Assignee: Alexion Pharmaceuticals, Inc.
    Inventors: Bruce A. Andrien, Jr., Douglas L. Sheridan, Paul P. Tamburini, Yi Wang
  • ANTI-C5 ANTIBODIES HAVING IMPROVED PHARMACOKINETICS
    Publication number: 20180009885
    Abstract: The disclosure provides antibodies that are useful for, among other things, inhibiting terminal complement (e.g., the assembly and/or activity of the C5b-9 TCC) and C5a anaphylatoxin-mediated inflammation and, thus, treating complement-associated disorders. The antibodies have a number of improved properties relative to eculizumab, including, e.g., increased serum half-life in a human.
    Type: Application
    Filed: September 19, 2017
    Publication date: January 11, 2018
    Inventors: Bruce A. ANDRIEN, JR., Douglas L. SHERIDAN, Paul P. TAMBURINI, Yi WANG
  • Anti-C5 antibodies having improved pharmacokinetics
    Patent number: 9803007
    Abstract: The disclosure provides antibodies that are useful for, among other things, inhibiting terminal complement (e.g., the assembly and/or activity of the C5b-9 TCC) and C5a anaphylatoxin-mediated inflammation and, thus, treating complement-associated disorders. The antibodies have a number of improved properties relative to eculizumab, including, e.g., increased serum half-life in a human.
    Type: Grant
    Filed: April 20, 2017
    Date of Patent: October 31, 2017
    Assignee: Alexion Pharmaceuticals, Inc.
    Inventors: Bruce A. Andrien, Jr., Douglas L. Sheridan, Paul P. Tamburini, Yi Wang
  • ANTI-C5 ANTIBODIES HAVING IMPROVED PHARMACOKINETICS
    Publication number: 20170298123
    Abstract: The disclosure provides antibodies that are useful for, among other things, inhibiting terminal complement (e.g., the assembly and/or activity of the C5b-9 TCC) and C5a anaphylatoxin-mediated inflammation and, thus, treating complement-associated disorders. The antibodies have a number of improved properties relative to eculizumab, including, e.g., increased serum half-life in a human.
    Type: Application
    Filed: April 20, 2017
    Publication date: October 19, 2017
    Inventors: Bruce A. ANDRIEN, JR., Douglas L Sheridan, Paul P. Tamburini, Yi Wang
  • Anti-C5 antibodies having improved pharmacokinetics
    Patent number: 9663574
    Abstract: The disclosure provides antibodies that are useful for, among other things, inhibiting terminal complement (e.g., the assembly and/or activity of the C5b-9 TCC) and C5a anaphylatoxin-mediated inflammation and, thus, treating complement-associated disorders. The antibodies have a number of improved properties relative to eculizumab, including, e.g., increased serum half-life in a human.
    Type: Grant
    Filed: May 20, 2016
    Date of Patent: May 30, 2017
    Assignee: Alexion Pharmaceuticals, Inc.
    Inventors: Bruce A. Andrien, Jr., Douglas L. Sheridan, Paul P. Tamburini, Yi Wang
  • ANTI-C5 ANTIBODIES HAVING IMPROVED PHARMACOKINETICS
    Publication number: 20160251433
    Abstract: The disclosure provides antibodies that are useful for, among other things, inhibiting terminal complement (e.g., the assembly and/or activity of the C5b-9 TCC) and C5a anaphylatoxin-mediated inflammation and, thus, treating complement-associated disorders. The antibodies have a number of improved properties relative to eculizumab, including, e.g., increased serum half-life in a human.
    Type: Application
    Filed: May 20, 2016
    Publication date: September 1, 2016
    Inventors: Bruce A. ANDRIEN, JR., Douglas L. Sheridan, Paul P. Tamburini
  • Anti-C5 antibodies having improved pharmacokinetics
    Patent number: 9371377
    Abstract: The disclosure provides antibodies that are useful for, among other things, inhibiting terminal complement (e.g., the assembly and/or activity of the C5b-9 TCC) and C5a anaphylatoxin-mediated inflammation and, thus, treating complement-associated disorders. The antibodies have a number of improved properties relative to eculizumab, including, e.g., increased serum half-life in a human.
    Type: Grant
    Filed: October 27, 2015
    Date of Patent: June 21, 2016
    Assignee: Alexion Pharmaceuticals, Inc.
    Inventors: Bruce A. Andrien, Jr., Douglas L. Sheridan, Paul P. Tamburini
  • ANTI-C5 ANTIBODIES HAVING IMPROVED PHARMACOKINETICS
    Publication number: 20160108115
    Abstract: The disclosure provides antibodies that are useful for, among other things, inhibiting terminal complement (e.g., the assembly and/or activity of the C5b-9 TCC) and C5a anaphylatoxin-mediated inflammation and, thus, treating complement-associated disorders. The antibodies have a number of improved properties relative to eculizumab, including, e.g., increased serum half-life in a human.
    Type: Application
    Filed: October 27, 2015
    Publication date: April 21, 2016
    Inventors: Bruce A. ANDRIEN, JR., Douglas L. SHERIDAN, Paul P. TAMBURINI
  • Nucleic acids encoding anti-C5 antibodies having improved pharmacokinetics
    Patent number: 9206251
    Abstract: The disclosure provides antibodies that are useful for, among other things, inhibiting terminal complement (e.g., the assembly and/or activity of the C5b-9 TCC) and C5a anaphylatoxin-mediated inflammation and, thus, treating complement-associated disorders. The antibodies have a number of improved properties relative to eculizumab, including, e.g., increased serum half-life in a human.
    Type: Grant
    Filed: July 1, 2015
    Date of Patent: December 8, 2015
    Assignee: Alexion Pharmaceuticals, Inc.
    Inventors: Bruce A. Andrien, Jr., Douglas L. Sheridan, Paul P. Tamburini
  • ANTI-C5 ANTIBODIES HAVING IMPROVED PHARMACOKINETICS
    Publication number: 20150299305
    Abstract: The disclosure provides antibodies that are useful for among other things, inhibiting terminal complement (e.g., the assembly and/or activity of the C5b-9 TCC) and C5a anaphylatoxin-mediated inflammation and, thus, treating complement-associated disorders. The antibodies have a number of improved properties relative to eculizumab, including, e.g., increased serum half-life in a human.
    Type: Application
    Filed: July 1, 2015
    Publication date: October 22, 2015
    Inventors: Bruce A. ANDRIEN, JR., Douglas L. Sheridan, Paul P. Tamburini
  • Methods of treating C5 mediated complement-associated conditions with anti-C5 antibodies having improved pharmacokinetics
    Patent number: 9107861
    Abstract: The disclosure provides antibodies that are useful for, among other things, inhibiting terminal complement (e.g., the assembly and/or activity of the C5b-9 TCC) and C5a anaphylatoxin-mediated inflammation and, thus, treating complement-associated disorders. The antibodies have a number of improved properties relative to eculizumab, including, e.g., increased serum half-life in a human.
    Type: Grant
    Filed: June 1, 2015
    Date of Patent: August 18, 2015
    Assignee: Alexion Pharmaceuticals, Inc.
    Inventors: Bruce A. Andrien, Jr., Douglas L. Sheridan, Paul P. Tamburini